$7.14
+0.0400 (+0.563%)
At Close: Jul 31, 2026
Kamada (NASDAQ:KMDA) Announces Earnings Results
03:58pm, Tuesday, 23'rd Nov 2021 Dakota Financial News
Kamada (NASDAQ:KMDA) issued its earnings results on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a return on equity of 6.73% and a net margin of 10.42%. During the same period last year, the firm posted $0.15 […]
Kamada (NASDAQ:KMDA) Releases Earnings Results, Misses Expectations By $0.05 EPS
03:06pm, Tuesday, 23'rd Nov 2021 Transcript Daily
Kamada (NASDAQ:KMDA) released its quarterly earnings data on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a net margin of 10.42% and a return on equity of 6.73%. During the same period in the prior year, the […]
Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript
05:07pm, Monday, 22'nd Nov 2021 Seeking AlphaKamada Stock Jumps After Acquisition Of Four Plasma-Derived Products
03:44pm, Monday, 22'nd Nov 2021 Benzinga
Kamada Ltd (NASDAQ: KMDA ) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics . Kamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034. The combined annual global revenue of the acquired portfolio in 2021 is expected to be $40 million - $45 Full story available on Benzinga.com
Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript
12:07pm, Monday, 22'nd Nov 2021
Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products
12:00pm, Monday, 22'nd Nov 2021 Intrado Digital Media
REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2021.
Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products
10:44am, Monday, 22'nd Nov 2021
Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a $95 million upfront payment and an additional
Kamada (KMDA) Reports Q3 Loss, Lags Revenue Estimates
09:59am, Monday, 22'nd Nov 2021
Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada: Q3 Earnings Insights
09:07am, Monday, 22'nd Nov 2021
Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Kamada earnings: here''s what to expect
02:01pm, Sunday, 21'st Nov 2021 Business Insider Markets
On November 22, Kamada will report latest earnings. Analysts on Wall Street predict Kamada will release earnings per share of $0.027. Track Kamada stock price in real-time on Markets Insider here. On November 22, Kamada
Zacks: Analysts Expect Kamada Ltd. (NASDAQ:KMDA) Will Announce Earnings of $0.03 Per Share
02:06am, Monday, 15'th Nov 2021 Transcript Daily
Wall Street brokerages expect Kamada Ltd. (NASDAQ:KMDA) to report earnings of $0.03 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with the lowest EPS estimate coming in at $0.02 and the highest estimate coming in at $0.03. Kamada posted earnings of $0.16 per share []
New Strong Sell Stocks for August 25th
11:34am, Wednesday, 25'th Aug 2021
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
Kamada Limited (KMDA) CEO Amir London on Q2 2021 Results - Earnings Call Transcript
02:50pm, Wednesday, 11'th Aug 2021
Kamada Limited (KMDA) CEO Amir London on Q2 2021 Results - Earnings Call Transcript
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates
11:00am, Wednesday, 11'th Aug 2021
Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sign In
Buy KMDA